Short-term efficacy of ticagrelor in acute ST-segment elevation myocardial infarction patients undergoing an...

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• ST-segment elevation myocardial infarction (STEMI) is a critical condition requiring prompt reperfusion.
• P2Y12 inhibitors are essential for preventing thrombotic events post-percutaneous coronary intervention (PCI).
• Comparing the efficacy of ticagrelor and clopidogrel in STEMI patients undergoing emergency PCI is clinically relevant.

Purpose of the Study:

• To compare the effectiveness of ticagrelor versus clopidogrel in improving myocardial perfusion.
• To evaluate the antiplatelet effects of ticagrelor and clopidogrel in STEMI patients.
• To assess blood flow and platelet inhibition in STEMI patients receiving emergency PCI.

Main Methods:

• Ninety-seven STEMI patients undergoing emergency PCI were randomized into ticagrelor and clopidogrel groups.
• Thrombolysis in Myocardial Infarction (TIMI) blood flow and corrected TIMI frame count (CTFC) assessed vessel perfusion.
• Thromboelastography (TEG) evaluated drug-induced antiplatelet effects, specifically ADP-induced platelet inhibition (ADP%) and maximal amplitude (MA_ADP).

Main Results:

• Higher incidence of TIMI grade III blood flow observed in the ticagrelor group compared to clopidogrel.
• Significantly lower CTFC in key coronary arteries (anterior descending, circumflex, right) in the ticagrelor group.
• Ticagrelor group showed significantly increased ADP-induced platelet inhibition (ADP%) and decreased MA_ADP at 2 hours and 7 days post-treatment.

Conclusions:

• Ticagrelor significantly enhances TIMI blood flow in STEMI patients undergoing emergency PCI.
• Ticagrelor exhibits a superior antiplatelet effect compared to clopidogrel in this patient population.
• These findings suggest ticagrelor may offer improved outcomes for STEMI patients receiving emergency PCI.